bioecon Member area
Technology · Health & biomedicine / Therapeutics & platforms

Sublingual Mucosal Peptide and Protein Delivery

Formulation platforms employing permeation enhancers and mucoadhesive films for needle-free sublingual systemic absorption of peptides (exenatide, liraglutide, insulin, low-dose IL-2) directly into venous blood.

Medicine & Pharmaceuticals Industrial Manufacturing Maturity 7/9 Risk: medium Pharma & biologics Biomanufacturing & Bio-industrial Production CH · EU · US · CN verified 2026-11-22 · 1 Sources (0 independent)

1 · What it gives

Sublingual mucosal peptide and protein delivery represents an advanced non-invasive drug administration modality, circumventing harsh gastric acid, digestive protease degradation, and first-pass hepatic metabolism. By delivering therapeutic peptides (e.g. desmopressin, insulin, GLP-1 analogues, calcitonin) through the non-keratinized, highly vascularized sublingual mucosa, drugs drain directly into the internal jugular veins and systemic venous circulation within minutes.

The primary pharmaceutical engineering hurdles—low mucosal permeability of macromolecules (>1,000 Da) and rapid involuntary salivary clearance—are solved using bio-adhesive fast-dissolving oral thin films, lipid nanoparticle matrices, and permeation enhancers (such as sodium N-[8-(2-hydroxybenzoyl)amino]caprylate [SNAC], bile salts, and zonula occludens toxin fragments). Continuous hot-melt extrusion and electrospinning allow commercial production of sublingual wafers achieving bioavailability exceeding 8–15% relative to subcutaneous injection with rapid onset kinetics (<10 minutes).

The key directions of this technology are:

  1. Permeation Enhancer Formulation Chemistry: Formulating non-toxic, transient tight-junction modulators (SNAC, Labrasol, sodium caprate) that facilitate paracellular and transcellular flux of hydrophilic peptides across the mucosal epithelium.
  2. Mucoadhesive Fast-Dissolving Thin Films: Engineering electrospun or solvent-cast polymer matrices (HPMC, pullulan, chitosan) that adhere to the sublingual fold and dissolve within 30–60 seconds without mastication.
  3. Enzymatic Peptidase Inhibition Systems: Incorporating reversible competitive aminopeptidase and carboxypeptidase inhibitors (aprotinin, EDTA, citric acid) into the micro-environment to prevent localized enzymatic hydrolysis.
  4. Lipid & Nanoparticle Carrier Encapsulation: Designing sub-100 nm self-nanoemulsifying drug delivery systems (SNEDDS) and bilosomes that shield peptides from salivary washing and promote passive trans-epithelial transport.

Sectoral value chain#

┌────────────────────────────────────────────────────────┐
│  Tier 1: Peptide API & Mucoadhesive Polymer Matrix     │
│  (HPMC, pullulan, chitosan, therapeutic peptide API)   │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 2: Chemical Permeation Enhancers & Protease Inh. │
│  (SNAC, sodium caprate, EDTA, organic buffer salts)    │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 3: Precision Thin Film / Tablet Manufacturing    │
│  (Hot-melt extrusion, continuous electrospinning, ODF) │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 4: Sublingual Mucosal Absorption & Vascular Flux │
│  (Rapid 30-sec disintegration, venous direct drainage) │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 5: Systemic Therapeutic Distribution             │
│  (Bypassing hepatic first-pass, AUC bioavailability)   │
└────────────────────────────────────────────────────────┘

Value chain levels#

LevelDescriptionKey inputs/outputs
Raw Polymer & Permeation Enhancer SynthesisHigh-purity synthesis and compendial qualification of GRAS-grade mucoadhesive polymers (pullulan, carboxymethylcellulose) and absorption enhancers (SNAC, bile acids).In: Pharmaceutical grade excipients, SNAC dry powder, compendial buffers.
Out: Homogeneous excipient lots certified under USP <1058> and Ph. Eur.
Peptide-Enhancer Micro-Particle FormulationCo-spray drying or supercritical fluid anti-solvent precipitation of therapeutic peptide with enzyme inhibitors and permeation enhancers into micro-granules (1–10 µm).In: Peptide bulk drug substance, citric acid, sodium caprate.
Out: Stabilized micro-particulate core complexes protecting peptide tertiary fold.
Continuous Film Casting & Die-CuttingSlot-die coating or precision hot-melt extrusion of polymer dope onto release liners, drying under controlled laminar air, and laser die-cutting into unit-dose sublingual wafers.In: Polymer-peptide dope slurry, PET carrier liners, precision slitters.
Out: Unit-dose fast-dissolving sublingual films with <3% weight uniformity CV.
Analytical In Vitro Permeation & Release TestingHigh-throughput Franz diffusion cell testing using porcine sublingual mucosal tissue and in-line UV-HPLC to quantify apparent permeability coefficient (Papp) and flux rates.In: Excised mucosal membranes, Franz cell arrays, physiological simulated saliva.
Out: Validated release profiles confirming >80% drug release in <2 minutes.
Hermetic Desiccant Strip PackagingAutomated high-speed packaging into cold-form aluminum-aluminum blister foils with integrated molecular sieve desiccants to ensure 24-month room temperature stability.In: Die-cut sublingual strips, aluminum barrier foil, desiccant liners.
Out: Commercial cGMP shelf-ready patient packs with tamper-evident seals.

Cross-cutting technologies of the sector:

  • Hot-Melt Extrusion (HME): Enables solvent-free, continuous thermal compounding of heat-sensitive peptide excipients without water-induced degradation.
  • Franz Cell Permeation Arrays: Provides standardized ex vivo mucosal flux modeling for regulatory bioequivalence submissions.
  • Barrier Packaging Technology: Protects highly hygroscopic fast-dissolving thin films against ambient humidity and degradation.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 4 steps

  1. 1
    Mucolytic and permeation formulation
    Blending transient tight-junction openers (bile salts, acylcarnitines, cyclodextrins) with therapeutic peptides.
  2. 2
    Fast-dissolving mucoadhesive sublingual wafer
    Continuous solvent casting of thin polymer wafers (pullulan, HPMC) adhering firmly under the tongue.
  3. 3
    Trans-epithelial flux optimization
    Achieving systemic bioavailability >15% without mucosal irritation or cellular cytotoxicity.
  4. 4
    Clinical pharmacokinetic benchmarking
    Demonstrating rapid Tmax (<15 min) and equivalent therapeutic glucodynamic or immunological response.

4 · Who delivers

Matched suppliers (matched automatically)

Lonza GroupSwitzerlandProduceractive
NovartisSwitzerlandProduceractive
GenScript ProBio / GenscriptChinaServices / consultingactive
21st.BIODenmarkProduceractive
A.COSTANTINO & C SPAItalyProduceractive
Spiber Technologies ABSwedenResearch / RTOactive
IsomeraseUnited KingdomProduceractive
Zero Cow FactoryIndiaProduceractive
Perfect DayUnited StatesProduceractive
QINGDAO SEAWIN BIOTECH GROUPChinaProduceractive

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
BioLingus🇨🇭 SwitzerlandSublingual Micro-Array PlatformPioneered non-invasive sublingual delivery platform for peptides, GLP-1, and biological vaccinesclinical
Novo Nordisk🇩🇰 DenmarkOral & Sublingual FormulationsPioneered SNAC carrier chemistry enabling mucosal and trans-epithelial peptide absorptioncommercial
Aquestive Therapeutics🇺🇸 United StatesPharmFilm Oral Film TechnologyGlobal leader in commercial polymer thin-film manufacturing for sublingual and buccal therapeuticscommercial
Midatech Pharma🇬🇧 United KingdomQ-Sphera / MidaSolveSpecialized micro-delivery developer utilizing gold nanoparticles and fast-dissolving oral wafersclinical
Catalent (RP Scherer)🇺🇸 United StatesZydis Fast-Dissolve TechnologyGold standard freeze-dried fast-dissolving wafer platform achieving sublingual disintegration in secondscommercial
NanoPass Technologies🇮🇱 IsraelMicronJet Mucosal DeliveryPrecision micro-pyramid arrays and mucosal infusion applicators for macromolecular drug deliverycommercial

5 · Rules & route to market

United States

FDA 505(b)(2) Reformulation Pathways & Bioequivalence Criteria#

  • The US FDA regulates sublingual peptide reformulations via the 505(b)(2) NDA mechanism, allowing sponsors to bridge to existing safety dossiers while demonstrating mucosal safety and non-inferiority to subcutaneous injections.
  • FDA draft guidances on sublingual products emphasize measuring local tissue tolerability, absence of mucosal ulceration over chronic 90-day dosing, and salivary wash-down swallowing fraction.
  • Commercial biotechs in Cambridge and San Diego are advancing sublingual GLP-1, parathyroid hormone (PTH), and epinephrine formulations to eliminate cold-chain autoinjector burdens.

European Union

Swiss Health Valley Mucosal Formulations & EMA Quality Standards#

  • Switzerland’s Lake Geneva cluster is a prominent hub for sublingual biopharmaceutical technology, led by pioneers like BioLingus developing sublingual micro-arrays for peptides and vaccines.
  • The European Medicines Agency (EMA) enforces strict quality guidelines regarding sublingual dissolution apparatus selection (Ph. Eur. 2.9.3) and in vitro-in vivo correlation (IVIVC) validation.
  • Academic-industrial partnerships across Switzerland, Germany, and Sweden explore sublingual allergen immunotherapy (SLIT) and peptide neuro-therapeutics.

China

Oral Mucosal Delivery Innovation & NMPA Priority Review#

  • In China, high patient reluctance toward chronic needle injections in pediatric and geriatric populations drives massive clinical interest in oral mucosal and sublingual delivery platforms.
  • Leading research institutes in Shanghai and Beijing (e.g. SIMM, China Pharmaceutical University) collaborate with domestic pharma to develop chitosan-coated lipid nanoparticles for sublingual peptide vaccines and hormones.
  • NMPA CDE guidelines prioritize patient-centric reformulations that show bioequivalence with fewer adverse gastrointestinal events than conventional oral tablets.

6 · Money: tenders & grants

7 · Tech stack & innovations

  1. Excipient Matrix & Mucoadhesion Architecture:
    • Polymeric matrix combining low-viscosity hydroxypropyl methylcellulose (HPMC E5) and pullulan in a 3:1 ratio.
    • Inclusion of 0.5% (w/w) sodium carboxymethylcellulose providing immediate mucosal tackiness within 3 seconds of wetting.
    • Disintegration time engineered to exactly 30–45 seconds in 0.5 mL simulated human saliva without leaving fibrous residue.
  2. Permeation Enhancement & Protection Kinetics:
    • Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) micronized to D50 < 3 µm and co-crystallized with peptide API at a 10:1 molar ratio.
    • Transient perturbation of epithelial lipid bilayer fluidity without cytotoxic cellular lysis (lactate dehydrogenase release <2%).
    • Apparent mucosal permeability coefficient (Papp) increased by 18-fold from 1.2x10^-7 cm/s to 2.2x10^-6 cm/s across excised porcine tissue.
  3. Continuous Film Casting & Stability Control:
    • Slot-die coating speed operating at 2.5 m/min with infrared drying zone maintaining web temperature strictly below 42°C.
    • Laser optical sensor array monitoring dry film thickness (target 65 µm ±2 µm) and real-time Karl Fischer moisture (<3.5%).
    • Automated high-speed punch and pouch machine packaging 600 strips/minute in triple-laminate aluminum foil under nitrogen purge.

Sources 1 · 0 independent · 1 producer sites

Producers' own sites 1

  1. www.swissbiotech.org producer checked 2026-11-22